Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.K)

TEVA.K on New York Consolidated

14.74USD
17 Oct 2017
Change (% chg)

$0.03 (+0.20%)
Prev Close
$14.71
Open
$14.75
Day's High
$14.97
Day's Low
$14.58
Volume
14,505,674
Avg. Vol
19,153,524
52-wk High
$44.42
52-wk Low
$14.30

Latest Key Developments (Source: Significant Developments)

Teva announces submission of biologics license application for Fremanezumab to U.S. FDA
8:00am EDT 

Oct 17 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva announces submission of biologics license application for Fremanezumab to the U.S. FDA.Teva Pharmaceutical Industries Ltd - ‍submission of a biologics license application to U.S. FDA for Fremanezumab​.  Full Article

BioDelivery sciences announces patent litigation settlement agreement with Teva
Thursday, 12 Oct 2017 07:00am EDT 

Oct 12 (Reuters) - Biodelivery Sciences International Inc :BioDelivery Sciences announces patent litigation settlement agreement with Teva.BioDelivery Sciences International Inc - ‍other terms of agreement are confidential​.BioDelivery Sciences - ‍as part of settlement agreement, co has entered into a non-exclusive license agreement with Teva ​.BioDelivery Sciences International - ‍ entered into settlement agreement with Teva Pharmaceuticals USA, Actavis Laboratories Ut, Teva Pharmaceuticals Industries.BioDelivery Sciences International Inc - ‍as part of settlement agreement BDSI has entered into a non-exclusive license agreement with Teva​.BioDelivery Sciences - settlement agreement permits Teva to first begin selling its generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier under certain circumstances.BioDelivery Sciences International - ‍ settlement agreement resolves BDSI's BUNAVAIL patent litigation against Teva pending in United States district court​.BioDelivery Sciences - ‍agreement with Teva permits Teva to first begin selling generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier​.  Full Article

Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate
Wednesday, 4 Oct 2017 09:26am EDT 

Oct 4 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate 40mg/ml and launch of generic Glatiramer Acetate 20mg/ml.‍Any launch by Mylan of generic version of Copaxone prior to final resolution of pending patent litigation should be considered "at-risk" launch​.‍Early assessment of impact of generic launches to earnings for Q4 ended Dec 31, 2017 is that it could be affected by at least $0.25 cents/share​.  Full Article

NY A.G. Schneiderman, coalition of AGs expand investigation into opioid crisis
Tuesday, 19 Sep 2017 12:39pm EDT 

Sept 19 (Reuters) - New York A.G. Schneiderman::New York A.G. Schneiderman, bipartisan coalition of AGs expand multistate investigation into opioid crisis.Says served subpoenas to Endo International, Janssen Pharmaceuticals, Teva Pharmaceutical/Cephalon Inc and Allergan.Says Attorneys General have also served a supplemental investigative subpoena on Purdue Pharma.Attorneys General demanded information about distribution practices from AmerisourceBergen, Cardinal Health, McKesson.  Full Article

Teva and Nuvelution Pharma partner to accelerate development of Austedo tablets for use in Tourette Syndrome in the united states
Tuesday, 19 Sep 2017 10:00am EDT 

Sept 19 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva and Nuvelution Pharma partner to accelerate development of austedo® (deutetrabenazine) tablets for use in tourette syndrome in the united states.Teva Pharmaceutical Industries Ltd - upon fda approval of austedo® in ts, teva will pay nuvelution a pre-agreed return on its invested capital.Teva - ‍under terms of agreement, Nuvelution will fund and manage clinical development, driving all operational aspects of Phase III Program​.Teva Pharmaceutical Industries Ltd - ‍ under terms, Teva will lead regulatory process and be responsible for commercialization of austedo tablets​.  Full Article

Edge Therapeutics appoints Rosemary Crane to Board of Directors
Tuesday, 19 Sep 2017 07:00am EDT 

Sept 19 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics appoints Rosemary A Crane, pharmaceutical industry leader, to its Board Of Directors.Edge Therapeutics Inc - ‍Crane's appointment expands Board of Directors to 10 members, eight of whom are independent​.Edge Therapeutics Inc - ‍Crane currently serves as a Director of Teva Pharmaceuticals and as vice chairman of Board of Zealand Pharma A/S​.  Full Article

Royal Unibrew CEO Jesper Jorgensen resigns
Monday, 18 Sep 2017 02:15pm EDT 

Sept 18 (Reuters) - Royal Unibrew A/S :Board of company and CEO Jesper B. Jorgensen have mutually agreed that Jesper B. Jorgensen resigns from his position.COO, Johannes F.C.M. Savonije will take over position as President & CEO of Royal Unibrew with effect as of Monday.Kare Schultz, has decided to retire from board of directors of Royal Unibrew with effect as of 1 January 2018.Royal Unibrew A/S - Board of directors has decided to appoint current deputy chairman of board of directors, Walther Thygesen, as chairman of board.Changes to board of directors will be effective as per 1 January 2018.  Full Article

Teva announces sale of remaining assets in women’s health portfolio for $1.38 bln
Monday, 18 Sep 2017 08:07am EDT 

Sept 18 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva announces sale of remaining assets in specialty global women’s health portfolio for $1.38 billion.Teva - ‍executes sale agreements for planned divestiture of global women's health business to generate total proceeds of $2.48 billion​.Teva - CVC Capital Partners fund VI to buy portfolio of products within co's global women's health business for $703 million in cash​.Teva-‍proceeds from sales, combined with proceeds from recent sale of paragard total $2.48 billion and will be used to progress repayment of term loan debt​.Teva Pharmaceutical Industries-‍foundation consumer healthcare to buy plan B One-Step, co's value brands of emergency contraception for $675 million in cash​.Teva Pharmaceutical - reinforcing "strategic focus" on CNS, respiratory as its core global therapeutic areas of focus within global specialty medicines​.Teva - ‍until transactions are completed, Teva will continue to market in normal course​ products involved in deals announced on Sept. 18.  Full Article

Teva receives FDA priority review for first line use of Trisenox
Tuesday, 12 Sep 2017 08:00am EDT 

Sept 12 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva receives fda priority review for first line use of trisenox® (arsenic trioxide) in patients with low to intermediate risk acute promyelocytic leukemia (apl).Teva Pharmaceutical Industries Ltd - ‍FDA has accepted SNDA for priority review with regulatory action expected in Q1 of 2018​.  Full Article

Cooper Companies announces agreement to acquire Paragard® IUD from Teva
Monday, 11 Sep 2017 04:15pm EDT 

Sept 12 (Reuters) - Cooper Companies Inc :The Cooper Companies announces definitive agreement to acquire Paragard® IUD from Teva.Cooper Companies Inc - boards of directors of both Cooper and Teva have unanimously approved transaction.Cooper Companies Inc - ‍excluding items, deal to be accretive to Cooper's gross and operating margins and about $0.70 to $0.75 accretive to EPS in year one​.Cooper Companies Inc - acquired business includes Teva's manufacturing facility in Buffalo, NY, which exclusively produces Paragard IUD.  Full Article